Published in Am J Respir Crit Care Med on June 15, 2014
Macrolide antibiotics for prevention of chronic obstructive pulmonary disease exacerbations: are we there yet? Am J Respir Crit Care Med (2014) 2.00
Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet (2015) 1.11
The chronic bronchitis phenotype in chronic obstructive pulmonary disease: features and implications. Curr Opin Pulm Med (2015) 0.98
Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis (2016) 0.83
A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2015) 0.81
Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS One (2015) 0.78
Prevention of COPD exacerbations: medications and other controversies. ERJ Open Res (2015) 0.78
Positioning new pharmacotherapies for COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.77
Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS One (2015) 0.77
Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res (2016) 0.76
Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation. Int J Chron Obstruct Pulmon Dis (2016) 0.76
[Acute exacerbations of COPD: Prophylactic antibiotics often makes sense]. MMW Fortschr Med (2014) 0.75
Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators. Drugs (2017) 0.75
Current status and inspiration on macrolides in the treatment of chronic obstructive pulmonary disease. J Transl Int Med (2015) 0.75
Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Sci Rep (2016) 0.75
Budesonide, fluticasone propionate, and azithromycin do not modulate the membrane vesicle release by THP-1 macrophages and respiratory pathogens during macrophage infection. Inflammopharmacology (2017) 0.75
[Pseudomonas aeruginosa infections in chronic obstructive pulmonary disease : Role of long-term antibiotic treatment]. Internist (Berl) (2017) 0.75
A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis (1992) 15.92
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med (2005) 4.95
Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev (2010) 2.32
Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest (2006) 1.98
Cigarette smoking and innate immunity. Inflamm Res (2008) 1.78
Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med (2013) 1.35
Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther (2009) 1.23
Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis (2011) 1.04
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med (2009) 9.38
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med (2005) 7.61
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
A randomized study of endobronchial valves for advanced emphysema. N Engl J Med (2010) 6.23
Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med (2010) 6.19
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69
Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med (2000) 5.65
Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest (2007) 5.01
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet (2004) 5.01
International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2006) 4.95
Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One (2011) 4.65
An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med (2013) 4.49
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40
Mechanisms of pulmonary fibrosis. Annu Rev Med (2004) 4.37
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 4.29
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med (2009) 4.05
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med (2011) 3.80
Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol (2002) 3.66
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A (2012) 3.43
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30
Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA (2004) 3.07
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
Comparison of spirometric thresholds in diagnosing smoking-related airflow obstruction. Thorax (2013) 2.88
Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med (2005) 2.86
Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med (2007) 2.80
Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med (2007) 2.77
Spirometry utilization for COPD: how do we measure up? Chest (2007) 2.77
Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology (2009) 2.75
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.71
A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest (2013) 2.71
Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med (2012) 2.65
Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg (2006) 2.53
Effect of occupational exposures on decline of lung function in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 2.48
Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab (2004) 2.47
beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med (2005) 2.45
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med (2006) 2.37
Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med (2003) 2.35
Risk of pancreatic cancer in families with Lynch syndrome. JAMA (2009) 2.32
Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest (2015) 2.32
Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med (2002) 2.24
Long-acting β2-agonist step-off in patients with controlled asthma. Arch Intern Med (2012) 2.24
Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc (2008) 2.20
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 2.20
Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2007) 2.19
Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease. Thorax (2012) 2.15
Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.10
Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J (2005) 2.09
Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.09
A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD (2012) 2.07
A frozen hell. Nature (2011) 2.07
Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study. Am J Respir Crit Care Med (2011) 2.06
Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann Am Thorac Soc (2013) 2.05
Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs (2004) 2.05
Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med (2007) 2.04
Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med (2003) 2.03
Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax (2013) 1.99